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Summary
Background:  The  indications  for  hemiarthroplasty  in  glenohumeral  joint  diseases  remain  contro-
versial and  depend  mainly  on  the  original  underlying  diagnosis.  Our  objective  was  to  investigate
the inﬂuence  of  the  primitive  aetiology  on  long-term  prosthesis  survival  and  on  the  Constant-
Murley score.
Materials  and  methods:  We  studied  272  shoulders  with  the  following  diagnoses:  fracture  seque-
lae (n  =  73),  primary  osteoarthritis  (n  =  67),  cuff  tear  arthropathy  (n  =  43),  avascular  necrosis
(n =  40),  rheumatoid  arthritis  (n  =  31),  and  other  (n  =  18).  Of  the  272  shoulders,  139  were  eval-
uated after  at  least  8  years  (mean  follow-up,  134  months).  In  all,  30  prostheses  required
removal.  Functional  status  was  evaluated  using  the  Constant-Murley  score  and  survival  rate
using the  Kaplan-Meier  method  with  prosthesis  removal  or  conversion  to  total  arthroplasty  as
the endpoint.
Results:  Ten-year  prosthesis  survival  was  88.13%  overall,  100%  in  the  rheumatoid  arthritis  group,
94.9% in  the  avascular  necrosis  group,  94.2%  in  the  primary  osteoarthritis  group,  81.5%  in  the
cuff tear  arthropathy  group,  and  76.8%  in  the  fracture  sequelae  (P  =  0.05).  The  mean  Constant-
Murley score  after  8  years  or  more  was  70.1  in  avascular  necrosis,  60.7  in  primary  osteoarthritis,
57.7 in  fracture  sequelae,  55.3  in  rheumatoid  arthritis,  and  46.2  in  cuff  tear  arthropathy
(P =  0.0006).  The  complication  rate  with  the  initial  population  as  the  denominator  was  24.7%
in fracture  sequelae,  18.6%  in  cuff  tear  arthropathy,  15%  in  avascular  necrosis,  8.9%  in  primary
osteoarthritis,  and  3.2%  in  rheumatoid  arthritis.
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Conclusions:  The  best  indication  for  shoulder  hemiarthroplasty  is  avascular  necrosis  and  the
worst indications  are  cuff  tear  and  post-traumatic  fracture  sequellae.  Rheumatoid  arthritis  and
primary  glenohumeral  osteoarthritis  are  good  indications  in  patients  younger  than  50  years  of
age.
Level of  evidence:  Level  IV,  retrospective  study.
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he  ﬁrst  case-series  of  shoulder  hemiarthroplasty  was
eported  by  Neer  in  1970  [1].  The  patients  had  four-part
roximal  humeral  fractures,  and  the  outcomes  were  good.
ince  then,  hemiarthroplasty  has  been  used  in  many  other
houlder  diseases  including  osteoarthritis  (OA)  [2],  avascu-
ar  necrosis  (AVN)  [3]  rheumatoid  arthritis  (RA)  [4],  cuff-tear
rthropathy  (CTA)  [5]  and  fracture  sequelae  (Seq)  [6].
mprovements  in  function,  motion  range,  and  pain  were
ften  substantial  in  AVN,  variable  in  OA  and  RA,  and  dis-
ppointing  in  CTA  and  Seq.  In  CTA,  the  reverse  prosthesis
eveloped  by  Grammont  et  al.  [7]  seems  more  effective
8].  Thus,  shoulder  hemiarthroplasty  is  widely  accepted
9—11]  for  patients  with  an  intact  rotator  cuff  and  little
r  no  glenoid  wear,  two  conditions  met  in  AVN.  However,
n  young  patients  with  glenoid  wear,  there  is  no  consensus
bout  the  optimal  type  of  arthroplasty  [10]. Hemiarthro-
lasty  can  result  in  glenoid  erosion,  which  is  the  main  cause
f  clinical  deterioration  and  short-  and  medium-term  revi-
ions  [12—14]. Total  shoulder  arthroplasty  carries  a  risk  of
lenoid  component  loosening,  which  becomes  increasingly
ommon  over  time  and  correlates  with  increased  pain  and
iminished  function  [15—18]. In  addition,  bone  stock  alter-
tions  are  common  after  total  shoulder  arthroplasty  and
omplicate  revision  surgery.  Consequently,  selection  of  the
est  type  of  prosthesis,  and  more  speciﬁcally  the  decision  to
erform  hemiarthroplasty,  should  be  based  on  factors  that
nﬂuence  prosthesis  survival  and  functional  outcomes.
Here,  our  objectives  were  to  evaluate  prosthesis  sur-
ival,  complications,  and  the  Constant-Murley  score  [19]  in
atients  evaluated  at  least  8  years  after  shoulder  hemi-
rthroplasty;  and  to  determine  whether  the  results  were
nﬂuenced  by  the  aetiology  of  the  shoulder  disorder.  Our
ypothesis  was  that  the  aetiology  would  substantially  affect
rosthesis  survival  and  functional  outcomes.
aterial and methods
e  conducted  a  retrospective  multicentre  European  study  of
ll  primary  shoulder  hemiarthroplasties  (Aequalis® Tornier
nc.,  Edina  MN,  USA)  performed  before  31st  December
000.  The  patients  were  evaluated  in  2009  to  establish  out-
omes  after  at  least  8  years.  All  indications  for  shoulder
emiarthroplasty  were  included  except  tumours  and  recent
ractures.  We  identiﬁed  272  consecutive  shoulder  hemi-
rthroplasty  procedures  performed  between  May  1988  and
ecember  2000.
The  272  procedures  were  done  in  261  patients  (11
atients  had  bilateral  surgery),  180  women  and  81  men
M/F  ratio,  1/2.22),  with  a  mean  age  at  surgery  of  59  years
U
o
t
Crights  reserved.
range,  16—82).  The  dominant  side  was  affected  in  57%  of
ases.  Two-thirds  of  patients  were  retired  or  had  no  paid
ccupation.  The  underlying  diagnoses  were  Seq  in  73  cases,
rimary  OA  in  67,  CTA  in  43,  AVN  in  40  (including  four  with
adiation-induced  necrosis),  RA  in  31,  instability  in  10,  and
iscellaneous  disorders  in  eight.
At  follow-up,  54  patients  with  59  hemiarthroplasties  had
ied  with  the  prosthesis  in  place  and  46  patients  with
7  hemiarthroplasties  had  been  lost  to  follow-up  without
ny  record  of  hemiarthroplasty  complications.  Among  the
61  remaining  patients,  with  166  hemiarthroplasties,  30
equired  prosthesis  removal  (including  3  after  at  least  8
ears)  and  12  experienced  complications  that  did  not  require
rosthesis  removal.  Thus,  134  patients  who  still  had  139
rostheses  were  re-evaluated  after  at  least  8  years;  mean
ollow-up  was  11.2  years  (range,  8—16.6  years).  Mean  age  at
e-evaluation  was  69.8  years  (range,  30—94  years).  Table  1
eports  the  distribution  across  underlying  aetiologies.
The  instability  and  miscellaneous  diagnoses  groups  were
oo  small  for  a  meaningful  statistical  analysis.  Despite  a
ong-standing  consensus  that  hemiarthroplasty  is  not  appro-
riate  in  CTA  [20], several  surgeons  were  reluctant  to  switch
o  reverse  arthroplasty  and  continued  to  perform  hemi-
rthroplasty  in  this  indication.
At  baseline,  the  non-weighted  and  weighted  Constant-
urley  scores  [19]  were  26.5%  and  34.4%,  respectively.
ctive  forward  elevation  was  78.4◦ and  active  external  rota-
ion  with  the  elbow  at  the  side  was  10.6◦. At  follow-up,  the
onstant-Murley  score  was  determined  and  active  motion
anges  in  forward  elevation  and  external  rotation  with  the
lbow  at  the  side  were  measured.  Poor  outcomes  were
eﬁned  as  any  of  the  following:  non-weighted  Constant-
urley  score  less  than  30,  weighted  Constant-Murley  score
ess  than  50%,  Constant-Murley  pain  item  subscore  less  than
0,  or  active  forward  elevation  less  than  90◦ with  active
xternal  rotation  elbow  at  the  side  less  than  10◦.
Prosthesis  survival  curves  were  established  using  the
aplan-Meier  method  [21]  with  computation  of  the  95%
onﬁdence  intervals  (95%CIs).  The  endpoint  was  pros-
hesis  removal  deﬁned  as  changing  the  humeral  stem,
onverting  to  total  arthroplasty,  or  performing  arthrode-
is.  Patients  who  died  with  their  prosthesis  in  place  were
ensored.
Each  aetiological  group  was  studied  separately.  Preop-
rative  and  postoperative  data  were  compared  using  the
ilcoxon  test  for  paired  data.  The  Constant-Murley  scores  at
ast  follow-up  at  least  8  years  after  hemiarthroplasty  were
ompared  across  aetiological  groups  using  the  Mann-Whitney
 test  and  the  Kruskal-Wallis  test  for  unpaired  data.  Values
f  P  smaller  than  0.05  were  considered  signiﬁcant.  Statis-
ical  analyses  were  done  using  Statview  software  (Abacus
oncepts  Inc.  Berkeley,  CA,  USA).
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Table  1  Distribution  of  the  hemiarthroplasties  according  to  aetiologies.
Aetiology  Initial
population
Follow-up
after  ≥  8  years
No  follow-up  Mean  agea
(years)
Mean  follow-up
(months)
Died  Lost  to
follow-up
Removal
(<  8  years)
Seq 73  34  13  14  12  59  140.5
OA 67 42 9 13 3  66  123.5
CTA 43 18 15 3 7  70  141.9
AVN 40 20 3 14 3 46 141.9
RA 31  14  14  3  0  41  144.5
Instability 10  5  4  0  1  65  128.7
Miscellaneous 8  6  1  0  1  59  115.5
Total 272 139  59  47  27  59  (16—82)b 134.4
(96—199)b
CTA: cuff tear arthropathy; OA: glenohumeral osteoarthritis; RA: rheumatoid arthritis; AVN: avascular necrosis; Seq: fracture sequelae.
a Age at surgery.
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Results
Over  the  entire  follow-up  period,  42  complications  were
recorded.  The  two  main  complications  were  pain  from
glenoid  erosion  (17  cases,  all  of  which  required  prosthesis
removal)  and  stiffness  (eight  cases,  of  which  ﬁve  required
prosthesis  removal).  The  other  complications  required
prosthesis  removal  in  eight  cases.  Table  2  reports  the
complications  and  cases  of  prosthesis  removal  by  under-
lying  aetiology.  Symptomatic  glenoid  erosion  was  an  early
complication  that  usually  occurred  within  the  ﬁrst  3  years;
however,  four  cases  occurred  after  at  least  8.5  years,  with
the  underlying  aetiologies  being  Seq  in  two  cases,  CTA  in  one
case,  and  AVN  in  one  case.  In  the  patient  with  AVN,  ante-
rior  wear  developed  gradually  after  a  subscapularis  tear  was
diagnosed  within  the  ﬁrst  postoperative  year.  Complication
rates  were  24.7%  in  the  Seq  group,  18.6%  in  the  CTA  group,
15%  in  the  AVN  group,  8.9%  in  the  primary  OA  group,  and
3.2%  in  the  RA  group.
Re-evaluation  of  the  139  shoulders  with  the  prosthesis  in
place  after  at  least  8  years  showed  signiﬁcant  improvements
in  the  Constant-Murley  score  and  in  each  of  its  compo-
nents  (Table  3).  The  greatest  gain  occurred  in  the  primary
OA  group,  with  a  33-point  increase.  Mean  Constant-Murley
scores  at  last  follow-up  after  at  least  8  years  differed  signiﬁ-
cantly  across  aetiological  groups  (P  =  0.0006):  70.1  (40—89)
in  AVN,  60.7  (9—93)  in  primary  OA,  57.7  (28—84)  in  Seq,
55.3  (36—87)  in  RA,  and  46.2  (24—77)  in  CTA.  The  Constant-
Murley  score  in  the  AVN  group  was  signiﬁcantly  higher  than
in  the  Seq  group  (P  =  0.0145),  RA  group  (P  =  0.0022),  and
CTA  group  (P  <  0.0001)  and  non-signiﬁcantly  higher  than  in
the  primary  OA  group  (P  =  0.082).  In  the  AVN  group,  the
range-of-motion  component  of  the  Constant-Murley  score
was  signiﬁcantly  better  than  in  all  other  aetiological  groups
(PFA,  P  =  0.0065;  RA,  P  =  0.003;  CTA,  P  =  0.0004;  and  pri-
mary  OA,  P  =  0.0124).  The  RA  group  had  the  best  pain
score  (although  the  difference  with  the  other  groups  was
not  statistically  signiﬁcant)  and  the  lowest  range-of-motion
score.
a
w
sTable  4  reports  the  poor  outcomes  by  aetiological  group.
onstant-Murley  score  values  less  than  30  occurred  in  17%
f  CTA  shoulders  and  12%  of  Seq  shoulders.  Pain  scores  less
han  10  were  seen  in  39%  of  CTA  shoulders  and  19%  of  primary
A  shoulders.  Limited  mobility  (forward  elevation  less  than
0◦ and  external  rotation  elbow  at  the  side  less  than  10◦)
as  noted  in  29%  of  RA  shoulders,  23%  of  Seq  shoulders,  and
2%  of  CTA  shoulders  (NS).  The  aetiological  group  with  the
owest  rate  of  poor  outcomes  was  AVN  (NS).
The  prosthesis  was  removed  in  30  cases.  Overall  pros-
hesis  survival  was  92.1%  after  5  years  and  88.13%  after  10
ears.  Prosthesis  survival  was  100%  in  the  RA  group,  94.9%
n  the  primary  OA  group,  94.2%  in  the  AVN  group,  81.5%  in
he  CTA  group,  and  76.8%  in  the  Seq  group.  Table  5  reports
urvival  rates  across  aetiological  groups  after  5  and  10  years
nd  Fig.  1  the  Kaplan-Meier  survival  curves,  which  indicated
igniﬁcant  differences  (P  =  0.05).  The  instability  group  and
he  group  of  miscellaneous  aetiologies  were  not  taken  into
ccount  in  the  survival  curve  analysis.  As  no  events  occurred
n  the  RA  group,  this  aetiology  is  not  indicated  on  the  curve.
urvival  rates  remained  stable  after  the  ﬁfth  year  in  the
rimary  OA  and  AVN  groups  but  continued  to  decline  signiﬁ-
antly  in  the  Seq  and  CTA  groups.
iscussion
he  indications  for  shoulder  hemiarthroplasty  in  patients
ith  glenohumeral  joint  disorders  remain  controversial.
otal  arthroplasty  carries  a  risk  of  glenoid  component  loos-
ning  in  the  long  term,  whereas  hemiarthroplasty  can  result
n  glenoid  erosion.  In  the  literature,  the  best  balance
etween  these  two  risks  is  unclear  but  seems  to  depend  on
oth  the  underlying  aetiology  and  patient-related  factors.
ur  study  establishes  that  the  aetiology  exerts  a  major  inﬂu-
nce  on  the  survival  of  shoulder  hemiarthroplasty  and  that high  prosthesis  survival  rate  fails  to  correlate  consistently
ith  good  functional  outcomes.
Our  study  has  a  number  of  limitations.  The  long  inclu-
ion  period  over  more  than  a  decade  explains  the  large
662
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Table  2  Distribution  of  complications  according  to  aetiologies  (number  of  complications/number  of  prostheses  removed).
Seq  (73)a OA  (67)a CTA  (43)a AVN  (40)a RA  (31)a Instability  (10)a Miscellaneous  (8)a Total  (272)a
Glenoid  erosion 7/7  3/3  4/4  3/3  17/17
Stiffness 1/1  2/0  2/2  1/0  1/1  1/1  8/5
Rotator cuff  tear  2/2  1/0  1/0  4/2
Infection 2/2  1/1  3/3
Humeral fracture  3/0  3/0
Anterior instability  1/1  1/1  2/2
Stem loosening  1/0  1/0  2/0
Tuberosity 1/1  1/1
Posterior instability  1/0  1/0
Hematoma 1/0  1/0
Total complication/removal  18/14  6/3  8/7  6/4  1/0  1/1  2/1  42/30
CTA: cuff tear arthropathy; OA: glenohumeral osteoarthritis; RA: rheumatoid arthritis; AVN: avascular necrosis; Seq: fracture sequelae.
a Number of prostheses in the initial population.
Table  3  Mean  Constant-Murley  scores  in  the  population  re-evaluated  after  at  least  8  years,  across  aetiologies.
Pain  ADL  Range  of  motion  Strength  Constant  score
Preoperatively Last  follow-up Preoperatively Last  follow-up Preoperatively Last  follow-up Preoperatively Last  follow-up Preoperatively Last  follow-up
AVN  (20)a 3.8 12.2 7.5 16.2 17.6 32.4 3.3 9.3  32.2  70.1
P 0.0001 0.0001 0.0003 0.002 0.0001
OA (42)a 3.3  11.4  6.4  15.1  13  26.5  4.3  7.7  27  60.7
P <  0.0001  <  0.0001  <  0.0001  0.0004  <  0.0001
Seq (34)a 4.7 11.2 6 14.6 13.6 24.8 5 7.1 29.3  57.7
P < 0.0001 <  0.0001 <  0.0001 0.0117 <  0.0001
RA (14)a 5.1  12.4  7.4  13.7  12.3  22  1.9  7.1  26.2  55.3
P 0.001  0.001  0.001  0.005  0.001
CTA (18)a 4.3 10.2 6 11 13.9 22.3 2.6 2.7 26.8 46.2
P 0.0006 0.0034 0.0031 0.234 0.0006
CTA: cuff tear arthropathy; OA: glenohumeral osteoarthritis; RA: rheumatoid arthritis; AVN: avascular necrosis; Seq: fracture sequelae.
a Number of prostheses in the population re-evaluated after at least 8 years.
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Figure  1  Prosthesis  survival  across  diagnostic  groups  (Kaplan-
Meier method;  asymmetric  95%  conﬁdence  interval  according  to
Rothman).
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most  notably  regarding  range  of  motion,  although  the  resultsOA: glenohumeral  osteoarthritis;  AVN:  avascular  necrosis;  CTA:
cuff tear  arthropathy;  PFA:  post-fracture  arthropathy.
number  of  patients  who  died  or  were  lost  to  follow-up.  The
choice  between  total  arthroplasty  and  hemiarthroplasty  was
at  the  discretion  of  each  surgeon,  and  the  criteria  may  have
varied  across  centres.  The  large  number  of  centres  and  out-
come  assessors  raises  concerns  about  the  reproducibility  of
the  clinical  evaluation.  The  number  of  patients  was  small  in
some  of  the  aetiological  groups.  Finally,  we  did  not  consider
the  radiographic  data,  particularly  glenoid  cavity  morphol-
ogy  at  baseline.
Prosthesis  survival  after  shoulder  hemiarthroplasty  is
important  to  consider  and  is  even  crucial  for  patients
younger  than  50  years  of  age.  In  a  study  of  patients
younger  than  50  years  with  a  mean  follow-up  of  16.2  years,
total  arthroplasty  was  superior  over  hemiarthroplasty,  with
10-year  survival  rates  of  97%  and  84%,  respectively  [22].
However,  the  underlying  aetiologies  were  not  clearly  dif-
ferentiated  in  this  study.
Few  studies  compared  long-term  outcomes  after  total
arthroplasty  and  hemiarthroplasty  in  AVN,  and  most  of
them  included  trauma-related  necrosis,  which  raises  spe-
ciﬁc  issues  [23,24].  After  a  mean  follow-up  of  8.9  years,
functional  outcomes  were  similar  with  the  two  procedures,
although  survival  was  better  with  total  arthroplasty  [23]. A
study  with  a  shorter  follow-up  of  4.8  years  found  no  clinical
differences  between  the  two  procedures  but  showed  a  22%
complication  rate  after  total  arthroplasty  compared  to  only
8%  after  hemiarthroplasty  [24]. The  94%  survival  rate  after
10  years  in  our  study  is  among  the  best  reported  to  date
and  is  consistent  with  the  95%  survival  rate  after  15  years
reported  in  an  earlier  study  [3].  These  good  results  after
hemiarthroplasty  are  all  the  more  relevant  that  the  patients
were  young  (46  years  in  our  re-evaluated  patients  with
AVN,  Table  1).  When  used  after  radiation-induced  necro-
sis,  hemiarthroplasty  has  produced  disappointing  outcomes
[25],  which  were  not  clearly  replicated  in  our  four  patients,
although  1  of  these  patients  developed  an  infection  requir-
ing  prosthesis  removal  within  the  ﬁrst  year.  Our  data  conﬁrm
o
t
f663
hat  AVN  is  a  reliable  indication  for  hemiarthroplasty  that  is
ssociated  with  excellent  tolerance  by  the  glenoid  in  the
ong  term,  regardless  of  the  cause  of  the  necrosis.
Two  prospective  randomised  studies  have  been  per-
ormed  in  primary  OA.  In  one  of  these  studies,  total
rthroplasty  produced  better  outcomes  for  pain,  mobility,
nd  revision  rates  [26]. The  other,  in  contrast,  showed  no
igniﬁcant  difference,  although  a  trend  in  favour  of  total
rthroplasty  was  noted  [27]. Follow-up  was  brief  in  both
tudies,  36  months  [26]  and  24  months  [27], respectively,
nd  the  results  cannot  be  extrapolated  to  the  long  term.
rosthesis  survival  after  hemiarthroplasty  was  86%  in  a  study
f  51  cases  with  a  follow-up  of  11.3  years  [28]  and  72%
n  a  study  of  20  cases  with  a  follow-up  of  7  years  [29].
ur  survival  rate  of  94.2%  after  10  years  is  among  the  best
eported  to  date.  In  all  three  cases  of  prosthesis  removal,
he  procedure  was  required  within  the  ﬁrst  18  months,
ecause  of  pain  due  to  glenoid  erosion.  In  another  study,
ean  time  to  revision  was  1.5  years  and  the  main  reason
or  prosthesis  removal  was  pain  due  to  glenoid  erosion  [14].
arly  occurrence  of  pain  may  be  due  to  wear  of  the  poste-
ior  glenoid  cavity  [30,31].  A  correlation  has  been  reported
etween  joint  space  narrowing  and  functional  outcomes
13]  but  there  is  no  consensus  about  the  source  of  pain  in
atients  with  glenoid  cartilage  erosion.  Nevertheless,  our
tudy  shows  that  hemiarthroplasty  is  a  reasonable  treatment
ption  in  primary  OA.  Although  total  arthroplasty  may  be
ore  effective  in  relieving  residual  pain,  hemiarthroplasty
oes  not  carry  the  risk  of  glenoid  component  loosening  with
one  stock  alteration  that  occurs  10  to  15  years  after  total
rthroplasty  in  young  patients.
A  study  in  RA  indicated  that  long-term  pain  relief  was
etter  after  total  arthroplasty  than  after  hemiarthroplasty,
xcept  in  patients  who  had  rotator  cuff  lesions  [4].  Pros-
hesis  survival  was  better  after  total  arthroplasty,  with  a
.6%  revision  rate  for  glenoid  component  failure,  compared
o  7.4%  for  pain  due  to  glenoid  erosion  after  hemiarthro-
lasty.  In  contrast,  the  survival  curve  was  stable  after
emiarthroplasty  starting  at  the  5th  year  but  continued  to
ecrease  after  total  arthroplasty,  so  that  the  two  curves
ntersected  eventually  (after  15—20  years).  In  another  study
f  RA  patients,  glenoid  component  loosening  with  upwards
igration  of  the  humeral  implant  due  to  rotator  cuff  tears
ccurred  in  42%  of  cases  [16]. A  study  with  a  follow-up  of
t  least  15  years  showed  that  glenoid  component  loosening
eveloped  in  87%  of  cases  and  rotator  cuff  tears  in  100%
f  cases  [32]. In  our  study,  the  10-year  prosthesis  survival
ate  in  the  RA  group  was  100%.  An  earlier  study  in  303  cases
ith  a  mean  follow-up  of  12.1  years  found  a 10-year  survival
ate  of  89%;  the  prosthesis  was  removed  in  10  cases,  the
eason  being  pain  from  glenoid  wear  in  eight  cases,  in  the
bsence  of  speciﬁc  predictive  factors  [4].  Our  case-series  is
oo  small  to  challenge  the  results  of  this  large  earlier  study
4].  The  mean  age  of  our  re-evaluated  patients  (40.5  years
n  our  re-evaluated  patients  with  RA,  Table  1)  was  younger,
nd  we  believe  the  good  prosthesis  survival  rate  supports
he  use  of  hemiarthroplasty  in  this  young  population.  The
unctional  outcomes  in  our  series  were  only  fair  overall,n  pain  were  satisfactory.  The  earlier  study  [4]  established
he  pain-relieving  effect  of  hemiarthroplasty  in  RA  [4].  This
avourable  effect  on  pain,  the  young  age  of  the  patients,  the
664  F.  Gadea  et  al.
Table  4  Distribution  of  poor  results  at  re-evaluation  after  at  least  8  years,  according  to  aetiology.
AVN  (20)a OA  (42)a Seq  (34)a RA  (14)a CTA  (18)a
Constant  <  30  (%)  0  3  (7)  6  (12)  0  3  (17)
Weighted Constant  <  50  (%)  1  (5)  5  (12)  8  (15)  1  (7)  4  (22)
Pain <  10  (%)  3  (15)  8  (19)  7  (13)  0  7  (39)
AFE <  90◦ +  AER  <  10◦ (%)  0  5  (12)  12  (23)  4  (29)  4  (22)
CTA: cuff tear arthropathy; GHOA: glenohumeral osteoarthritis; RA: rheumatoid arthritis; AVN: avascular necrosis; Seq: fracture sequelae;
AFE: active forward elevation; AER: active external rotation.
a Number of prostheses in the population re-evaluated after at least 8 years, used as the denominator for the percentages given in
parentheses.
Table  5  5-year  and  10-year  prosthesis  survival  rates  according  to  diagnoses.
Diagnosis Initial  population 5  years 10  years
Remaining  shoulders  Survival  rate  Remaining  shoulders  Survival  rate
RA  31  16  1  11  1
OA 67  46  0.949  19  0.949
AVN 40  25  0.942  15  0.942
CTA 43  25  0.885  14  0.815
Seq 73  43  0.816  25  0.768
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RCTA: cuff tear arthropathy; OA: glenohumeral osteoarthritis; RA: 
isk  of  glenoid  component  loosening  in  the  long  term,  and
he  good  prosthesis  survival  rate  support  hemiarthroplasty
ather  than  total  arthroplasty  in  patients  with  RA  aged  less
han  50  years,  despite  the  limited  effect  on  range  of  motion.
In  CTA,  total  arthroplasty  carries  a  risk  of  glenoid
omponent  loosening  [33], and  hemiarthroplasty  produces
isappointing  results  with  loss  of  motion  and  upwards
umeral  head  migration  that  erodes  the  acromial  vault  [34].
n  our  study,  this  group  had  the  worst  functional  outcomes
nd  a  low  prosthesis  survival  rate.  There  is  now  a  consensus
hat  reverse  arthroplasty  is  indicated  in  CTA,  except  in  very
oung  patients,  and  produces  far  better  functional  outcomes
han  does  hemiarthroplasty  [35].
In  the  Seq  group,  outcomes  after  hemiarthroplasty  were
ot  as  good  as  those  reported  after  ﬁrst-line  hemiarthro-
lasty  for  fracture  treatment  [36]. The  prosthesis  survival
ate  of  76.8%  in  this  aetiological  group  was  the  lowest
ecorded  in  our  study.  Thus,  hemiarthroplasty  does  not  seen
eliable  in  patients  with  Seq.  The  low  survival  rate  was  due  in
arge  part  to  revisions  because  of  glenoid  erosion,  suggesting
 far  greater  degree  of  cartilage  damage  than  estimated  on
he  radiographs.  The  analysis  of  poor  outcomes  in  this  group
26%)  and,  above  all,  the  high  rate  of  prosthesis  removal
how  that  Seq  is  a  poor  indication  for  hemiarthroplasty.
t  least  in  elderly  patients,  when  the  need  for  replace-
ent  surgery  has  been  established,  total  arthroplasty  seems
referable.
In  conclusion,  AVN  is  undoubtedly  the  best  indication  for
emiarthroplasty.  Primary  OA  and  RA  in  patients  younger
han  50  years  of  age  are  also  good  indications,  given  the
igh  rate  of  long-term  glenoid  component  loosening  after
otal  arthroplasty,  particularly  when  the  rotator  cuff  is  torn
which  is  common  in  RA  and  affects  a  substantial  number
f  patients  with  primary  OA).  In  contrast,  hemiarthroplastyatoid arthritis; AVN: avascular necrosis; Seq: fracture sequelae.
hould  be  viewed  with  circumspection  in  patients  with  CTA
r  Seq,  as  the  results  are  disappointing.  The  best  option  is
o  doubt  reverse  total  arthroplasty  in  CTA  and  either  total
r  reverse  total  arthroplasty  in  Seq  depending  on  the  nature
f  the  lesions.
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